Ernexa Therapeutics Inc. (ERNAW) Operating cash flow 2016–2025
Ernexa Therapeutics Inc. (ERNAW) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$7.0MFY2025 · since FY2016: $23,000 → -$7.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$7.0M | +55.7% |
| FY2024 | -$15.8M | +22.4% |
| FY2023 | -$20.4M | +2.7% |
| FY2022 | -$21.0M | +10.7% |
| FY2021 | -$23.5M | -189.9% |
| FY2020 | -$8.1M | -395.2% |
| FY2019 | $2.7M | +101.0% |
| FY2018 | $1.4M | +148.6% |
| FY2017 | $549,000 | +2287.0% |
| FY2016 | $23,000 | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ERNAW financial trends
ERNAW RevenueERNAW Net incomeERNAW Net marginERNAW Gross profitERNAW Gross marginERNAW Operating incomeERNAW Operating marginERNAW Free cash flowERNAW Capital expendituresERNAW Return on equityERNAW Stock buybacksERNAW Dividends paidERNAW Total assetsERNAW Total liabilitiesERNAW Shareholders’ equityERNAW overview →